Compare abrdn Income Credit Strategies Fund (ACP) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Tempus AI — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Tempus AI trades at $56.88 (market cap $10.79B). The key difference: Tempus AI is far larger — about 16.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| ACP | TEM | |
|---|---|---|
Market Cap | $656.21M | $10.79B |
Sector | Financials | Broad Market / Factor |
52-Week High | $5.98 | $103.25 |
52-Week Low | $5.01 | $42.37 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $11.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Tempus AI (TEM) trades at $60.70, up 0.71% with a bullish technical signal. The stock shows strong analyst support with 8 buy ratings and a $63.50 consensus target, though fundamentals reveal challenges with a -22.2% net margin and -$245M net loss for 2025. Recent FDA approvals and AI platform expansions drive positive sentiment, while cash flow remains dependent on financing activities.
Outlook remains cautiously optimistic given TEM's unique AI healthcare data platform and expanding partnerships, but investors face significant execution risks amid persistent losses. The stock's 7.85 P/S ratio reflects growth expectations, yet profitability concerns and high cash burn require careful monitoring for sustainable turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
